Stocks of the Hour: Telix Pharmaceuticals, Australian Unity Office Fund & Yancoal

Company News

by Lauren Evans

Telix Pharmaceuticals’ (ASX:TLX) prostate cancer imaging agent Illuccix® has been granted a pass-through in the US with full reimbursement available from July 1. The product will also be available to order for nationwide delivery to all positron emission tomography imaging sites in Australia. Shares are trading 6.8 per cent higher at $4.57.

Australian Unity Office Fund (ASX:AOF) has received a non-binding takeover bid from Aliro Group to acquire all shares for $2.45 per share. The company's largest shareholder, Hume Partners said it intends to vote its 20 per cent stake in favour of the proposal. The deal is subject to a number of conditions. Shares are trading 10.1 per cent higher at $2.41.

Yancoal’s (ASX:YAL) biggest shareholder Yankuang Energy is considering growing its stake in the coal miner, which may result in the de-listing of Yancoal shares on the Hong Kong stock exchange. However, Yancoal said there is no certainty that the transaction will proceed and Yancoal shareholders should not take any action. Shares are trading 13.8 per cent lower at $5.24.


Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.